Future Perspectives: Key Trends Shaping the Candida Infection Testing Market Until 2030

The candida infection testing market is gaining significant traction as advancements in diagnostic technologies and increasing awareness about fungal infections drive demand. With evolving testing methodologies and expanding applications, the market is set to experience notable growth in the coming years. Let's explore the market size projections, influential players, prevailing trends, and the segmentation landscape shaping this field.

Forecasted Market Size and Growth of the Candida Infection Testing Market
The candida infection testing market is projected to reach a substantial value of $22.56 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.1%. This upward trend is fueled by a rising need for rapid fungal diagnostics, a growing preference for molecular and microbiome-based testing methods, and the broadening availability of point-of-care fungal diagnostic tools. Investments targeting infectious disease diagnostics and a stronger emphasis on personalized antifungal treatments also contribute to this promising expansion. Key trends driving the market include the widespread adoption of molecular candida detection, increased use of rapid NAAT-based tests, integration of microbiome analyses, growth of hospital-centered fungal diagnostics, and a focus on early-stage fungal infection identification.

Download a free sample of the candida infection testing market report:
https://www.thebusinessresearchcompany.com/report/candida-infection-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Organizations Steering the Candida Infection Testing Market
Several prominent companies dominate the candida infection testing industry, including Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Cepheid, Randox Laboratories Ltd., Meridian Bioscience Inc., DiaSorin S.p.A., Sekisui Diagnostics LLC, Enzo Biochem Inc., T2 Biosystems Inc., Aidian Oy, SafeCare LLC, CHROMagar, HK Biotek Inc., Health Testing Centers LLC, Accesa Labs LLC, and Private MD Labs LLC.
A notable recent development occurred in February 2024 when Bruker Corporation finalized its acquisition of ELITechGroup for roughly €870 million (approximately $942 million) in cash. This strategic acquisition enhances Bruker's offerings in molecular diagnostics and infectious disease testing by integrating ELITech's cutting-edge technologies. ELITechGroup, headquartered in France, is recognized as a global leader in the in vitro diagnostics (IVD) sector.

Current Trends Influencing the Candida Infection Testing Field
In the contract sterilization segment related to infectious disease diagnostics, companies are concentrating on expanding ethylene oxide (EtO) sterilization capacities. This includes introducing new EtO service lines and upgrading multimodal sterilization facilities to address the escalating need for sterile medical devices and improve process efficiency.
Ethylene oxide sterilization is a low-temperature chemical technique that employs EtO gas to eradicate microorganisms on heat-sensitive or moisture-sensitive medical devices without compromising their structure or function. For example, in July 2023, STERIS Corporation, a US-based provider of medical equipment and sterilization services, unveiled new X-ray sterilization capabilities at its Kuala Ketil, Malaysia facility. This addition complements its existing gamma and EtO sterilization services, expanding overall sterilization capacity to support medical device manufacturers in Asia-Pacific. The center operates as a contract sterilization hub and adheres to ISO 13485 standards, serving as an integral part of STERIS's global sterilization network designed to meet routine and growing regional demands.

The candida infection testing market is gaining significant traction as advancements in diagnostic technologies and increasing awareness about fungal infections drive demand. With evolving testing methodologies and expanding applications, the market is set to experience notable growth in the coming years. Let's explore the market size projections, influential players, prevailing trends, and the segmentation landscape shaping this field.

Forecasted Market Size and Growth of the Candida Infection Testing Market
The candida infection testing market is projected to reach a substantial value of $22.56 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.1%. This upward trend is fueled by a rising need for rapid fungal diagnostics, a growing preference for molecular and microbiome-based testing methods, and the broadening availability of point-of-care fungal diagnostic tools. Investments targeting infectious disease diagnostics and a stronger emphasis on personalized antifungal treatments also contribute to this promising expansion. Key trends driving the market include the widespread adoption of molecular candida detection, increased use of rapid NAAT-based tests, integration of microbiome analyses, growth of hospital-centered fungal diagnostics, and a focus on early-stage fungal infection identification.

Download a free sample of the candida infection testing market report:
https://www.thebusinessresearchcompany.com/report/candida-infection-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Organizations Steering the Candida Infection Testing Market
Several prominent companies dominate the candida infection testing industry, including Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Cepheid, Randox Laboratories Ltd., Meridian Bioscience Inc., DiaSorin S.p.A., Sekisui Diagnostics LLC, Enzo Biochem Inc., T2 Biosystems Inc., Aidian Oy, SafeCare LLC, CHROMagar, HK Biotek Inc., Health Testing Centers LLC, Accesa Labs LLC, and Private MD Labs LLC.
A notable recent development occurred in February 2024 when Bruker Corporation finalized its acquisition of ELITechGroup for roughly €870 million (approximately $942 million) in cash. This strategic acquisition enhances Bruker's offerings in molecular diagnostics and infectious disease testing by integrating ELITech's cutting-edge technologies. ELITechGroup, headquartered in France, is recognized as a global leader in the in vitro diagnostics (IVD) sector.

Current Trends Influencing the Candida Infection Testing Field
In the contract sterilization segment related to infectious disease diagnostics, companies are concentrating on expanding ethylene oxide (EtO) sterilization capacities. This includes introducing new EtO service lines and upgrading multimodal sterilization facilities to address the escalating need for sterile medical devices and improve process efficiency.
Ethylene oxide sterilization is a low-temperature chemical technique that employs EtO gas to eradicate microorganisms on heat-sensitive or moisture-sensitive medical devices without compromising their structure or function. For example, in July 2023, STERIS Corporation, a US-based provider of medical equipment and sterilization services, unveiled new X-ray sterilization capabilities at its Kuala Ketil, Malaysia facility. This addition complements its existing gamma and EtO sterilization services, expanding overall sterilization capacity to support medical device manufacturers in Asia-Pacific. The center operates as a contract sterilization hub and adheres to ISO 13485 standards, serving as an integral part of STERIS's global sterilization network designed to meet routine and growing regional demands.

Breakdown of Market Segments and Share in the Global Candida Infection Testing Market
This report segments the candida infection testing market as follows:
1) By Type: Invasive Candidiasis, Candidemia
2) By Test Type: Vaginal pH Test, Nucleic Acid Amplification Testing (NAAT), Microbiome Test
3) By Application: Hospital, Laboratory

Further subcategories include:
- For Invasive Candidiasis: Tissue Biopsy Testing, Urine Culture Testing, Blood Culture Testing
- For Candidemia: Blood Tests, Serological Testing, Molecular Testing

These classifications provide a detailed view of the market's structure, highlighting critical areas of focus for diagnostics and their corresponding testing methods.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.